Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-63.03	-69.2	-88.1	-98.59	-60.73	-30.49
Depreciation & Amortization	4.85	4.81	4.89	3.67	2.5	1.33
Share-Based Compensation	9.05	9.22	9.58	8.5	1.42	0.51
Other Operating Activities	-13.75	-14.36	-2.87	29.35	9.5	2.31
Operating Cash Flow	-62.88	-69.53	-76.5	-57.07	-47.31	-26.34
Capital Expenditures	-0.2	-0.21	-1.95	-2.34	-3.26	-0.51
Change in Investments	52.45	71.24	59.82	-229.86	-17.33	0
Investing Cash Flow	52.25	71.04	57.86	-232.2	-20.59	-0.51
Share Issuance / Repurchase	0.25	0.25	0.5	259.21	0.29	0.07
Debt Issued / Paid	0	0	0	0	0	-0.04
Other Financing Activities	-	-	-	51.9	39.3	48.6
Financing Cash Flow	0.25	0.25	0.5	311.11	39.6	48.63
Net Cash Flow	-10.37	1.77	-18.14	21.84	-28.3	21.78
Free Cash Flow	-63.08	-69.73	-78.46	-59.4	-50.57	-26.85
Free Cash Flow Margin	-557.05%	-885.36%	-1369.47%	-4714.60%	-21891.77%	-12488.84%
Free Cash Flow Per Share	-1.66	-1.84	-2.10	-1.79	-24.05	-13.47

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).